![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPT-2101 is a sustained-release steroid formulation designed for precise inner ear administration using Spiral's novel delivery procedure. Spiral recently completed enrollment of an open label pilot clinical study of SPT-2101 in 10 patients with Meniere's disease.
Lead Product(s): SPT-2101
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SPT-2101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Savoir Capital
Deal Size: $8.2 million Upfront Cash: Undisclosed
Deal Type: Financing January 10, 2023